Resveratrol is one of 1037 small molecule programs targeting Insulin resistance. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
1931 competitors in COVID-19
Resveratrol
Precedex
Nitrostat
Rayaldee
Piperacillin/tazobactam
Statins
Achromycin V
Orap
Biological Data
Olokizumab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details